Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889546915> ?p ?o ?g. }
- W2889546915 abstract "ABSTRACT Background The receptor for advanced glycation end products (RAGE) modulates the pathogenesis of acute respiratory distress syndrome (ARDS). RAGE inhibition was recently associated with attenuated lung injury and restored alveolar fluid clearance (AFC) in a mouse model of ARDS. However, clinical translation will first require assessment of this strategy in larger animals. Methods Forty-eight anaesthetised Landrace piglets were randomised into a control group and three treatment groups. Animals allocated to treatment groups underwent orotracheal instillation of hydrochloric acid i) alone; ii) in combination with intravenous administration of a RAGE antagonist peptide (RAP), a S100P-derived peptide that prevents activation of RAGE by its ligands, or iii) in combination with intravenous administration of recombinant soluble (s)RAGE that acted as a decoy receptor. The primary outcome measure was net AFC at 4 h. Arterial oxygenation was assessed hourly for 4 h and alveolar-capillary permeability, alveolar inflammation, lung histology and lung mRNA expression of the epithelial sodium channel (α1-ENaC), α1-Na,K-ATPase and aquaporin (AQP)-5 were assessed at 4 h. Findings Treatment with either RAP or sRAGE improved net AFC rates (median [interquartile range], 21.2 [18.8–21.7] and 19.5 [17.1–21.5] %/h, respectively, versus 12.6 [3.2–18.8] %/h in injured, untreated controls), improved oxygenation and decreased alveolar inflammation and histological evidence of tissue injury after acid-induced ARDS. RAGE inhibition also restored lung mRNA expression of α1-Na,K-ATPase and AQP-5. Interpretation RAGE inhibition restored AFC and attenuated lung injury in a piglet model of acid-induced ARDS. Funding Auvergne Regional Council, Agence Nationale de la Recherche, Direction Générale de l’Offre de Soins . Research in Context Evidence before this study The acute respiratory distress syndrome (ARDS), a clinical syndrome of diffuse pulmonary oedema and inflammation, currently lacks effective therapies and is associated with high mortality and morbidity. The degrees of lung epithelial injury and of alveolar fluid clearance (AFC) impairment, as evaluated by plasma levels of soluble receptor for glycation end-products (RAGE), are major prognostic factors in ARDS and potential therapeutic targets for ongoing research. For example, targeting RAGE with recombinant sRAGE or an anti-RAGE monoclonal antibody has proven beneficial in a translational mouse model of acid-induced ARDS. Added value of this study In a piglet model of acid-induced ARDS, treatment with RAGE antagonist peptide or recombinant sRAGE restored AFC and attenuated the features of lung injury, thereby confirming, in the closest evolutionary model species to humans, previous evidence from rodent models that modulation of RAGE may be a therapeutic option for ARDS. Although this is an important step towards future clinical translation, future studies should assess the best methods to modulate RAGE and further confirm the safety of manipulating this pathway in patients with ARDS." @default.
- W2889546915 created "2018-09-07" @default.
- W2889546915 creator A5005956369 @default.
- W2889546915 creator A5007481932 @default.
- W2889546915 creator A5010790844 @default.
- W2889546915 creator A5013394355 @default.
- W2889546915 creator A5016207778 @default.
- W2889546915 creator A5032487737 @default.
- W2889546915 creator A5036740993 @default.
- W2889546915 creator A5039185776 @default.
- W2889546915 creator A5052422271 @default.
- W2889546915 creator A5053859235 @default.
- W2889546915 creator A5057178157 @default.
- W2889546915 creator A5057601919 @default.
- W2889546915 creator A5077019788 @default.
- W2889546915 creator A5077770617 @default.
- W2889546915 creator A5085911180 @default.
- W2889546915 date "2018-08-31" @default.
- W2889546915 modified "2023-09-24" @default.
- W2889546915 title "Inhibition of the Receptor for Advanced Glycation End-Products in Acute Respiratory Distress Syndrome: A Randomised Laboratory Trial in Piglets" @default.
- W2889546915 cites W1516729494 @default.
- W2889546915 cites W1549965729 @default.
- W2889546915 cites W1803784511 @default.
- W2889546915 cites W1921068641 @default.
- W2889546915 cites W1973087506 @default.
- W2889546915 cites W1974324988 @default.
- W2889546915 cites W1986067129 @default.
- W2889546915 cites W1990819855 @default.
- W2889546915 cites W1991940875 @default.
- W2889546915 cites W1996044520 @default.
- W2889546915 cites W2005033167 @default.
- W2889546915 cites W2007473062 @default.
- W2889546915 cites W2013725292 @default.
- W2889546915 cites W2014440780 @default.
- W2889546915 cites W2037948061 @default.
- W2889546915 cites W2058781586 @default.
- W2889546915 cites W2071259499 @default.
- W2889546915 cites W2087519450 @default.
- W2889546915 cites W2093142300 @default.
- W2889546915 cites W2093758142 @default.
- W2889546915 cites W2104938297 @default.
- W2889546915 cites W2105799653 @default.
- W2889546915 cites W2108640552 @default.
- W2889546915 cites W2109334664 @default.
- W2889546915 cites W2114081875 @default.
- W2889546915 cites W2114445825 @default.
- W2889546915 cites W2115672224 @default.
- W2889546915 cites W2116580258 @default.
- W2889546915 cites W2124536609 @default.
- W2889546915 cites W2124694442 @default.
- W2889546915 cites W2130072278 @default.
- W2889546915 cites W2142332363 @default.
- W2889546915 cites W2144304154 @default.
- W2889546915 cites W2145430092 @default.
- W2889546915 cites W2149354716 @default.
- W2889546915 cites W2156086455 @default.
- W2889546915 cites W2160369507 @default.
- W2889546915 cites W2171809815 @default.
- W2889546915 cites W2183958885 @default.
- W2889546915 cites W2281274792 @default.
- W2889546915 cites W2286228001 @default.
- W2889546915 cites W2289862791 @default.
- W2889546915 cites W2302682587 @default.
- W2889546915 cites W2610582798 @default.
- W2889546915 cites W2739498582 @default.
- W2889546915 cites W2883789215 @default.
- W2889546915 cites W4236805817 @default.
- W2889546915 cites W4237939525 @default.
- W2889546915 cites W4296816736 @default.
- W2889546915 doi "https://doi.org/10.1101/405423" @default.
- W2889546915 hasPublicationYear "2018" @default.
- W2889546915 type Work @default.
- W2889546915 sameAs 2889546915 @default.
- W2889546915 citedByCount "0" @default.
- W2889546915 crossrefType "posted-content" @default.
- W2889546915 hasAuthorship W2889546915A5005956369 @default.
- W2889546915 hasAuthorship W2889546915A5007481932 @default.
- W2889546915 hasAuthorship W2889546915A5010790844 @default.
- W2889546915 hasAuthorship W2889546915A5013394355 @default.
- W2889546915 hasAuthorship W2889546915A5016207778 @default.
- W2889546915 hasAuthorship W2889546915A5032487737 @default.
- W2889546915 hasAuthorship W2889546915A5036740993 @default.
- W2889546915 hasAuthorship W2889546915A5039185776 @default.
- W2889546915 hasAuthorship W2889546915A5052422271 @default.
- W2889546915 hasAuthorship W2889546915A5053859235 @default.
- W2889546915 hasAuthorship W2889546915A5057178157 @default.
- W2889546915 hasAuthorship W2889546915A5057601919 @default.
- W2889546915 hasAuthorship W2889546915A5077019788 @default.
- W2889546915 hasAuthorship W2889546915A5077770617 @default.
- W2889546915 hasAuthorship W2889546915A5085911180 @default.
- W2889546915 hasBestOaLocation W28895469151 @default.
- W2889546915 hasConcept C126322002 @default.
- W2889546915 hasConcept C134018914 @default.
- W2889546915 hasConcept C147990577 @default.
- W2889546915 hasConcept C169760540 @default.
- W2889546915 hasConcept C170493617 @default.
- W2889546915 hasConcept C203014093 @default.
- W2889546915 hasConcept C2776348555 @default.
- W2889546915 hasConcept C2776914184 @default.
- W2889546915 hasConcept C2777714996 @default.